{{Drugbox
| IUPAC_name = (8''S'',13''S'',14''S'',17''S'')-17-[(2''S'')-2-Hydroxypropanoyl]-13,17-dimethyl-1,2,6,7,8,11,12,13,14,15,16,17-dodecahydro-3''H''-cyclopenta[a]phenanthren-3-one
| image = Trimegestone.svg
| width = 250
| tradename = Ondeva, Totelle Sekvens
| CAS_number = 74513-62-5
| ATC_prefix = G03
| ATC_suffix = FA16
| PubChem = 68926
| DrugBank = 
| ChemSpiderID = 62152
| ChEMBL = 2104765
| KEGG = D06235
| C=22 | H=30 | O=3
| molecular_weight = 342.472 g/mol
| smiles = C[C@@H](C(=O)[C@]1(CC[C@@H]2[C@@]1(CCC3=C4CCC(=O)C=C4CC[C@@H]23)C)C)O
| synonyms = RU-27987
| StdInChI = 1S/C22H30O3/c1-13(23)20(25)22(3)11-9-19-18-6-4-14-12-15(24)5-7-16(14)17(18)8-10-21(19,22)2/h12-13,18-19,23H,4-11H2,1-3H3/t13-,18+,19-,21-,22+/m0/s1
| StdInChIKey = JUNDJWOLDSCTFK-MTZCLOFQSA-N
| bioavailability = 100%<ref name="FRCOG2015" />
| protein_bound = 
| metabolism = Mainly [[hydroxylation]]<ref name="Kuhl2009" />
| elimination_half-life = 13.8&nbsp;hours<ref name="Kuhl2009" />
| excretion = 
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = <!-- A / B / C / D / X -->
| pregnancy_category = 
| legal_AU = <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled-->
| legal_CA = <!-- Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_UK = <!-- GSL, P, POM, CD, or Class A, B, C -->
| legal_US = <!-- OTC / Rx-only / Schedule I, II, III, IV, V -->
| legal_status = Rx-only
| routes_of_administration = [[Oral administration|Oral]]
}}

'''Trimegestone''' ([[International Nonproprietary Name|INN]]) (brand names '''Ondeva''', '''Totelle Sekvens''' (both in [[combination drug|combination]] with [[estrogen]])) is a [[steroid]]al [[progestin]] of the [[19-norprogesterone]] group related to [[promegestone]] which is marketed in [[Europe]] as a [[hormonal contraceptive]] and for use in [[hormonal replacement therapy]] for [[postmenopause|postmenopausal symptom]]s.<ref name="GanellinTriggle1996">{{cite book|author1=C.R. Ganellin|author2=David J. Triggle|title=Dictionary of Pharmacological Agents|url=https://books.google.com/books?id=A0THacd46ZsC&pg=PA2063|date=21 November 1996|publisher=CRC Press|isbn=978-0-412-46630-4|pages=2063–}}</ref><ref name="OttowWeinmann2008">{{cite book|author1=Eckhard Ottow|author2=Hilmar Weinmann|title=Nuclear Receptors as Drug Targets|url=https://books.google.com/books?id=iATfLbPgRugC&pg=PA208|date=8 September 2008|publisher=John Wiley & Sons|isbn=978-3-527-62330-3|pages=208–}}</ref><ref name="Cutler2009">{{cite book|author=Winnifred Cutler|title=Hormones and Your Health: The Smart Woman's Guide to Hormonal and Alternative Therapies for Menopause|url=https://books.google.com/books?id=e1dhVE_ba48C&pg=PA43|date=30 March 2009|publisher=John Wiley & Sons|isbn=978-0-470-52553-1|pages=43–}}</ref><ref name="AcademicPress2012">{{cite book|title=Annual Reports in Medicinal Chemistry|url=https://books.google.com/books?id=y7GH165YoOsC&pg=PA647|date=31 December 2012|publisher=Academic Press|isbn=978-0-12-397214-9|pages=273, 647}}</ref><ref name="pmid12215716">{{cite journal | vauthors = Stanczyk FZ | title = Pharmacokinetics and potency of progestins used for hormone replacement therapy and contraception | journal = Rev Endocr Metab Disord | volume = 3 | issue = 3 | pages = 211–24 | year = 2002 | pmid = 12215716 | doi = 10.1023/A:1020072325818| url = }}</ref>

==Pharmacology==
Trimegestone has very high [[affinity (pharmacology)|affinity]] for the [[progesterone receptor]], only weak affinity for the [[mineralocorticoid receptor]], and little or no affinity for other [[steroid hormone receptor]]s.<ref name="OttowWeinmann2008" /><ref name="Cutler2009" /><ref name="LemkeWilliams2012"/> In accordance, it is described as a very [[potency (pharmacology)|potent]] and pure [[progestogen]],<ref name="OttowWeinmann2008"/> in fact the most potent progestin of the 19-norprogesterone group (clinically effective in [[endometriosis]] at only 0.1&nbsp;mg/day),<ref name="OttowWeinmann2008" /><ref name="Cutler2009" /><ref name="Kuhl2009">{{cite journal|last1=Kuhl|first1=H|title=Pharmacology of estrogens and progestogens: influence of different routes of administration|journal=Climacteric|volume=8|issue=sup1|year=2009|pages=3–63|issn=1369-7137|doi=10.1080/13697130500148875|url=http://hormonebalance.org/images/documents/Kuhl%2005%20%20Pharm%20Estro%20Progest%20Climacteric_1313155660.pdf|pmid=16112947}}</ref> and possesses weak [[antimineralocorticoid]] activity and no [[androgen]]ic, [[antiandrogen]]ic, [[estrogen]]ic, or [[glucocorticoid]] activity.<ref name="Kuhl2009" /><ref name="pmid14667983" /> Unlike [[progesterone (medication)|progesterone]], trimegestone does not [[metabolism|metabolize]] into [[neurosteroid]]s and hence does not influence [[GABAA receptor|GABA<sub>A</sub> receptor]] signaling or produce [[sedative]] [[side effect]]s.<ref name="pmid14667983">{{cite journal | vauthors = Winneker RC, Bitran D, Zhang Z | title = The preclinical biology of a new potent and selective progestin: trimegestone | journal = Steroids | volume = 68 | issue = 10-13 | pages = 915–20 | year = 2003 | pmid = 14667983 | doi = 10.1016/s0039-128x(03)00142-9| url = }}</ref>

==Pharmacokinetics==
The [[oral administration|oral]] [[bioavailability]] of trimegestone is 100%.<ref name="FRCOG2015">{{cite book|author=Howard J.A. Carp, MB, BS, FRCOG|title=Progestogens in Obstetrics and Gynecology|url=https://books.google.com/books?id=Ik8SCAAAQBAJ&pg=PA38|date=9 April 2015|publisher=Springer|isbn=978-3-319-14385-9|pages=38–}}</ref> Its [[elimination half-life]] is 13.8&nbsp;hours.<ref name="Kuhl2009" /> It is [[metabolism|metabolized]] mainly via [[hydroxylation]].<ref name="Kuhl2009" />

==Chemistry==
{{See also|List of steroidal progestogens}}
Trimegestone is a [[19-norpregnane]] [[steroid]] and a [[chemical derivative|derivative]] of [[19-norprogesterone]] (19-norpregn-4-ene-3,20-dione) and [[17α-methylprogesterone]]. It is also known as '''21(''S'')-hydroxy-17α,21-dimethyl-9-dehydro-19-norprogesterone'''<sup>?</sup> or '''21(''S'')-hydroxy-17α,21-dimethyl-19-norpregna-4,9-dien-3,20-dione'''<sup>?</sup>, as well as '''17β-(''S'')-lactoyl-17α-methylestra-4,9-dien-3-one''' or '''17β-((''S'')-2-hydroxypropanoyl)-17α-methylestra-4,9-dien-3-one'''.

Trimegestone is closely related structurally to the 19-norprogesterone and 17α-methylprogesterone derivatives [[demegestone]] and [[promegestone]] and is also known as '''21-hydroxypromegestone'''. It is also related to the 19-norprogesterone derivatives [[gestonorone caproate]], [[nomegestrol acetate]], [[norgestomet]], and [[segesterone acetate]] and to the 17α-methylprogesterone derivative [[medrogestone]].

==History==
Trimegestone was first introduced in 2001.<ref name="AcademicPress2012" /><ref name="TaylorTriggle2007">{{cite book|author1=John Bodenhan Taylor|author2=D. J. Triggle|title=Comprehensive Medicinal Chemistry II: Global perspective|url=https://books.google.com/books?id=KH0vAQAAIAAJ|year=2007|publisher=Elsevier|isbn=978-0-08-044514-4}}</ref>

==Society and culture==

===Brand names===
Trimegestone is marketed in combination with an [[estrogen]] under the brand names '''Ondeva''' and '''Totelle Sekvens'''.<ref name="TaylorTriggle2007" /><ref name="pmid12215716" /><ref name="BernardelliGaudillière2002">{{cite journal|last1=Bernardelli|first1=Patrick|last2=Gaudillière|first2=Bernard|last3=Vergne|first3=Fabrice|title=Chapter 26. To market, to market - 2001|volume=37|year=2002|pages=257–277|issn=0065-7743|doi=10.1016/S0065-7743(02)37027-1|journal=Annual Reports in Medicinal Chemistry}}</ref>

===Availability===
Trimegestone is marketed in [[France]] and [[Sweden]] and possibly also in other [[Europe]]an countries.<ref name="pmid12215716" /><ref name="Doherty2002">{{cite book|author=Annette M. Doherty|title=Annual Reports in Medicinal Chemistry|url=https://books.google.com/books?id=fT6NTDby3zUC&pg=PA273|year=2002|publisher=Elsevier|isbn=978-0-12-040537-4|pages=273–}}</ref> It is not available in the [[United States]].<ref name="LemkeWilliams2012">{{cite book|author1=Thomas L. Lemke|author2=David A. Williams|title=Foye's Principles of Medicinal Chemistry|url=https://books.google.com/books?id=Sd6ot9ul-bUC&pg=PA1403|date=24 January 2012|publisher=Lippincott Williams & Wilkins|isbn=978-1-60913-345-0|pages=1403–}}</ref>

==References==
{{Reflist|2}}

{{Progestogens and antiprogestogens}}
{{Progesterone receptor modulators}}
{{Mineralocorticoid receptor modulators}}

[[Category:Antimineralocorticoids]]
[[Category:Diketones]]
[[Category:Norpregnanes]]
[[Category:Progestogens]]


{{steroid-stub}}
{{genito-urinary-drug-stub}}